Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, was featured in a recent equity research report. The coverage, initiated by Maxim Group LLC, highlights MINDCURE’s efforts to set the stage to unlock value for the company. This includes work on its ongoing programs and clinical development, including synthetic ibogaine, for which it is planning a preclinical study with its research partner to initially conduct cardiac and neurological screens with data and potentially move into behavioral studies. In addition, the company plans to schedule a pre-IND meeting for its Desire Project in the first quarter of 2022 with a P2 planned for the third quarter of 2022 and has also initiated a candidate selection program for two additional pipeline compounds. Further, “For iSYTRM, MINDCURE has exceeded its initial target for the minimum viable product (‘MVP’) launch, securing 20 partner clinics (from a target of 10 by YE21). Full deployment is expected in C1Q22, with expansion to Europe by 4Q22. An additional internally developed ketamine protocol is expected to be released in C1Q22,” the report reads. “Key in 2021 for MINDCURE has been to continue to ‘block and tackle’ to best position the company in a rapidly evolving psychedelic-based medicines space. As such, while valuation has pulled back this year, the pieces should be in place to start to unlock value in MCUR/MCURF shares in 2022.”
To view the full report, visit https://ibn.fm/REyWD
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.